The table provides details of approved research proposals that have published or presented their results.
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Publication |
|---|---|---|---|---|
| 4036 | Akira Kimata | University of Tsukuba | Optimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials | Circulation. Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019, Volume: 140, Issue: 25, Pages: e965-e1011, DOI: (10.1161/CIR.0000000000000742) 10.1161/CIR.0000000000000742 |
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa/ | Clinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data Frew, John W. et al. Journal of the American Academy of Dermatology, Volume 0, Issue 0 https://doi.org/10.1016/j.jaad.2019.12.044 |
Publications about Vivli and Data Sharing
Bierer, B. E., Li, R., Barnes, M., & Sim, I. (2016). A Global, Neutral Platform for Sharing Trial Data.New England Journal of Medicine, 374(25), 2411–2413. https://doi.org/10.1056/NEJMp1605348.
Li, R. (2019). Move Clinical Trial Data Sharing from an Option to an Imperative – STAT First Opinion. [online] STAT.
Li, R., J. Scott, F. Rockhold, N. Hill, J. Wood, and I. Sim. (2018). Moving Data Sharing Forward: The Launch of the Vivli Platform . NAM Perspectives. Commentary, National Academy of Medicine, Washington, DC.
